Tag Archives: pfizer

Novo REDEFINE 1 Post Hoc Analyses; Ascletis Preclinical QW Oral Peptide Data; Pfizer Berobenatide OSA Study; AZ/Oracle AI Partnership; Lilly/METiS LNP-Delivery Technology Partnership

A series of cardiometabolic-related news items has been observed from Novo, Ascletis Pharma, Pfizer, AstraZeneca/Oracle, and Lilly/METiS TechBio. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA Clearance

A series of cardiometabolic-related news items has been observed from EMA, Pfizer, Novo/Ablexis, Fractyl Health, FDA/Lilly, MiniMed, and Sequel Med Tech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novartis Terminates Ph3 Pelacarsen Studies; AZ Partners with insitro; Dexcom Publishes CONNECT RCT Results; Pfizer China-Based QM Berobenatide Obesity Study; Modular Medical Digital Learning Tool; Medtronic Finalizes MiniMed Separation; Atrogi Oral GRK2-Biased ß2-Adrenergic Modulator Data

A series of cardiometabolic-related news items has been observed from Novartis, AstraZeneca, Dexcom, Pfizer, Modular Medical, MiniMed, and Atrogi AB. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Winners/Not Winners Analysis: Who Came Out on Top… and Who Didn’t?

Following EASD 2026 (Sep 28-Oct 2; Milan, Italy), FENIX has conducted a winners/not winners analysis, assessing which companies gained further momentum from the conference, remained static, or trended in the wrong direction. Spoiler alert: Lilly clearly came out on top, with EloraTZP setting a new efficacy benchmark for what may be achievable with an amylin + incretin combination. However, winning is not a zero-sum game…

This content is for Read Less members only.

Already a member? Log in here

Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI Development

Three cardiometabolic-related news items have been observed: Pfizer initiated the Ph3 QM berobenatide VESPER-OSA 1 study (view CT.gov record); Novo initiated the zenagamtide AMAZE 10 study in Japanese patients with obesity (view CT.gov record); and Novo and Anthropic entered into a collaboration to accelerate Novo’s drug development and AI-driven software development (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Vertex New Trial for T1DM Cell Therapy; Novo New Oral Anti-Inflammatory Study; Novo Leadership Transition; Pfizer Amylin Market-Shaping Campaign

A series of cardiometabolic-related news items has been observed from Vertex, Novo Nordisk, and Pfizer. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity Study

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its QW oral small-molecule GLP-1RA (view CT.gov record); Lilly received FDA approval for Mounjaro’s CVRR label expansion based on the SURPASS-CVOT study (view press release); and Pfizer initiated a Ph3 berobenatide study in an obese Chinese population (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ/BMS Merger to Challenge CVRM Leaders?; Novo Business Updates; Merck, Pfizer, Amgen, and Arrowhead Q2 ’26 Earnings; Ascletis Initiates Ph3 Oral GLP-1RA Program; Lilly Reta Expanded Access; Corbus CB1 Update

A series of cardiometabolic-related news items has been observed from AZ/BMS, Novo Nordisk, Merck, Pfizer, Amgen, Arrowhead Pharmaceuticals, Ascletis Pharma, Lilly, and Corbus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items, including insights into how the rumored AZ/BMS merger may impact the future CVRM market.

This content is for Read Less members only.

Already a member? Log in here

Altimmune Topline Ph2 Pemvidutide AUD Data; GSK Q2 ’26 Earnings; New Pfizer Ph1 Oral GLP-1RA Study; Antag Ph2a GIP Antagonist Study; Salubris Ph2 Lp(a) Study

A series of cardiometabolic-related news items has been observed from Altimmune, GSK, Pfizer, Antag Therapeutics, and Shenzhen Salubris Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here